Orthocell (ASX:OCC) reported revenue of AU$9.2 million for the fiscal year ended June 30, up almost 36% on the previous financial year, and AU$2.7 million for the June quarter, up almost 23% on the previous quarter, according to a Wednesday Australian bourse filing.
It added that the result is the fifth consecutive quarter of record revenue for the firm and that it does not include revenue from sales of its nerve repair product Remplir in the US.
It has focused on the execution of its US sales rollout plan for Remplir during the June quarter.
The firm's shares fell 2% in early trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.